Blue Trust Inc’s Vivos Therapeutics VVOS Stock Holding History

Blue Trust Inc’s Portfolio VVOS Stock Details VVOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$73	Hold	160	–	–	﹤0.01%	2416
2026 Q1	$189	Hold	160	–	–	﹤0.01%	2414
2025 Q4	$325	Hold	160	–	–	﹤0.01%	2448
2025 Q3	$496	Hold	160	–	–	﹤0.01%	2427
2025 Q2	$506	Hold	160	–	–	﹤0.01%	2320
2025 Q1	$456	Hold	160	–	–	﹤0.01%	2366
2024 Q4	$686	Hold	160	–	–	﹤0.01%	2306
2024 Q3	$355	Hold	160	–	–	﹤0.01%	2823
2024 Q2	$773	Hold	160	–	–	﹤0.01%	2567
2024 Q1	$773	Sell	160 -3,840	-96%	-$22.9K	﹤0.01%	1972
2023 Q4	$1K	Buy	4,000 +3,840	+2,400%	+$32.9K	﹤0.01%	2435
2023 Q3	$2K	Hold	160	–	–	﹤0.01%	1861
2023 Q2	$1K	Hold	160	–	–	﹤0.01%	1953
2023 Q1	$2K	Hold	160	–	–	﹤0.01%	2062
2022 Q4	$3K	Hold	160	–	–	﹤0.01%	1875
2022 Q3	$5K	Hold	160	–	–	﹤0.01%	1593
2022 Q2	$11K	Buy	+160	New	+$6.65K	﹤0.01%	1184

Other funds holding VVOS

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

IWM

IHT Wealth Management Chicago, Illinois $4.7B AUM 25.67% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

CWM

Centurion Wealth Management Mclean, Virginia $418M AUM 23.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SFA

Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return

Blue Trust Inc's VVOS Position: Q2 2026 in Review

Blue Trust Inc held its Vivos Therapeutics (VVOS) position steady in Q2 2026 at 160 shares worth $73. The position accounts for ﹤0.01% of the portfolio, ranked #2416.

Blue Trust Inc first reported a position in VVOS in Q2 2022 and has held it in 17 quarters since. The position peaked at $11K in Q2 2022. 23 funds tracked by Wall St. Rank hold VVOS as of Q2 2026.

Blue Trust Inc held 160 shares of Vivos Therapeutics worth $73 as of Q2 2026.
Blue Trust Inc left its Vivos Therapeutics share count unchanged in Q2 2026.
Vivos Therapeutics made up ﹤0.01% of Blue Trust Inc's portfolio in Q2 2026, its #2416 holding.
Blue Trust Inc first reported a position in Vivos Therapeutics in Q2 2022 and has held it in 17 quarters since.
Blue Trust Inc's Vivos Therapeutics position peaked at $11K in Q2 2022.
23 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q2 2026.

Based on Blue Trust Inc's 13F filing for Q2 2026, filed 21 Jul 2026.